Indivior Pharmaceuticals, Inc. Increase Decrease Through Financing Cash Flows Liabilities Arising From Financing Activities
Indivior Pharmaceuticals, Inc. (INDV) reported Increase Decrease Through Financing Cash Flows Liabilities Arising From Financing Activities of $53.00 million for the 12-month period ending 2023-12-31, per its 20-F filed 2024-03-06.
Discontinued › Cash Flow › Operating Activities
ifrs-full:IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities · last filed 2024-03-06
| Period end | Increase Decrease Through Financing Cash Flows Liabilities Arising From Financing Activities 12 month |
|---|---|
| 2023-12-31 | $53.00M 20-F · filed 2024-03-06 |
| 2022-12-31 | $102.00M 20-F · filed 2024-03-06 |
| 2021-12-31 | $345.00M 20-F · filed 2024-03-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |